INFASURF® is a medication used to treat respiratory distress syndrome (RDS), a lung condition that can occur in prematurely born infants whose lungs have not completely developed.

INFASURF® treats and prevents RDS. RDS occurs when infants lack surfactant, a natural substance normally produced in the body, which is necessary for lungs to function normally. INFASURF® is used exclusively in hospitals with a neonatal intensive care unit (NICU) and is administered by neonatologists, neonatal nurses, neonatal nurse practitioners and respiratory therapists. INFASURF® has been used in over 100,000 infants.

Administration of exogenous surfactants, including INFASURF®, often rapidly improve oxygenation and lung compliance. Following INFASURF® administration, patients should be monitored so that oxygen and ventilatory support can be modified. During dosing with INFASURF®, the most common adverse reactions reported in clinical trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), and ETT reflux (21%). These events were generally transient, and not associated with serious complications. If any of these events occur, administration should be interrupted and the infant's condition stabilized.

COUNTRY RESIDENCY NOTICE
The above information is intended for use only by residents of Turkey, Serbia, Bosnia, Macedonia, Albania, Egypt and Syria. Countries outside of those mentioned above may have regulatory requirements or medical practices that are different and may require reference to different or additional information. Therefore, this information may not be appropriate outside of those countries listed above.

Infasurf is an approved FDA prescription product owned by ONY, Inc. and marketed by Forest Labs in the US.

Currently, Samaritan Pharmaceuticals is utilizing the US FDA approved regulatory file in preparing marketing applications for Infasurf with regulatory authorities in Turkey, Serbia, Bosnia, F.Y.R.O.M., Albania, Egypt and Syria to gain country marketing authorization drug approval.

This Web site is intended and designed specifically for healthcare professionals from Turkey, Serbia, Bosnia, F.Y.R.O.M., Albania, Egypt, and Syria only. If you are a healthcare professional practicing your profession in a country other than those mentioned above, please visit http://www.frx.com/ to find information about Infasurf® outside of the countries listed above.